Metagenomi utilizes metagenomics and machine learning to discover and develop novel genome editing systems that enable precise modifications to the human genome. This technology addresses the limitations of existing gene editing methods by providing a versatile toolbox capable of targeting specific sites for therapeutic interventions.
Funding
$100M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CCSLFounders
Product
Problem
Existing genome editing technologies face limitations in targeting specific sites within the human genome, hindering the development of effective therapeutic interventions for a wide range of diseases. Current methods often lack the versatility and precision required for complex gene modifications.
Solution
Metagenomi leverages metagenomics and machine learning to discover and develop novel genome editing systems, creating a versatile toolbox for precise modifications to the human genome. By exploring uncultivated organisms in natural environments, Metagenomi identifies and engineers novel proteins into genetic medicines. The company's approach enables highly efficient, specific, and targetable genome editing tools, overcoming the limitations of existing technologies. This allows for precise correction of the human genome for a given therapeutic target.
Target Audience
The primary target audience includes researchers and pharmaceutical companies focused on developing curative therapies for genetic diseases through precise and targeted genome editing.
Features
- Discovery platform leveraging artificial intelligence and metagenomics expertise to recover novel cellular systems.
- High-throughput screening and AI-driven algorithms for rapid mining of billions of novel proteins.
- Programmable nucleases for gene knock-outs or knock-ins.
- Base editors for single base pair changes.
- RNA- and DNA-mediated integration systems for inserting or deleting large sections of the human genome.
- Prime editing systems and CASTs (CRISPR-associated transposases).